Sleep Disorders Drug Development Pipeline Review, 2017

1
Sleep Disorders Drug Development Pipeline Review,
2017
2
Summary

• This report provides an overview of the pipeline
  landscape for sleep disorders. The report
  provides comprehensive information on the
  therapeutics under development and key players
  involved in therapeutic development for Restless
  Legs Syndrome, Nocturia and Insomnia, and
  features dormant and discontinued projects.
• Restless Legs Syndrome is a neurologic disorder
  with a core feature of a distressing,
  irresistible need or urge to move the legs. Risk
  factors for RLS include low iron levels, kidney
  failure, Parkinson's disease, diabetes mellitus,
  rheumatoid arthritis, and pregnancy.
• Nocturia, or nocturnal polyuria, describes the
  excessive urination during night time. Nocturia
  becomes more common with age and may be
  symptomatic of the use of diuretic substances,
  prescription drugs, edema from heart failure,
  insomnia, pain and prostate or bladder disorders.

3
(No Transcript)
4

• Finally, insomnia is a sleep disorder that is
  characterized by difficulty in falling or staying
  asleep. Symptoms include difficulty falling
  asleep at night, waking up during the night,
  irritability, depression and anxiety.
• The size of these pipelines ranges from eight
  products in restless legs syndrome and nocturia
  to 31 in insomnia. Across all three of these
  indications there is a diverse range of molecular
  targets due to the different pathologies of the
  indications. The most common targets for restless
  legs syndrome, nocturia and insomnia therapeutics
  are D2 dopamine receptor, vasopressin V2 receptor
  and orexin receptor, respectively.

5
Scope

• Which companies are the most active within the
  pipeline for pneumonia therapeutics?
• Which pharmaceutical approaches are the most
  prominent at each stage of the pipeline and
  within each indication?
• To what extent do universities and institutions
  play a role within this pipeline, compared to
  pharmaceutical companies?
• What are the most important RD milestones and
  data publications to have happened in the field
  of pneumonia?

6
Reasons to buy

• Understand the overall pipeline, with an
  at-a-glance overview of all products in
  therapeutic development for each indication
• Assess the products in development in granular
  detail, with an up-to-date overview of each
  individual pipeline program in each indication,
  and a comprehensive picture of recent updates and
  milestones for each
• Analyze the companies, institutions and
  universities currently operating in the pipeline,
  and the products being fielded by each of these
• Understand the composition of the pipeline in
  terms of molecule type, molecular target,
  mechanism of action and route of administration

7
Related Reports

• Global Genetic disorders Partnering 2010-2017
  Deal trends, players and financials
• Global Hearing Disorders Partnering 2010 to 2017
• Global Sleep Disorders Partnering 2010 to 2017
• Behavioral Disorders Drug Development Pipeline
  Review, 2017
• Glycogen Storage Disorders (GSD) Global Clinical
  Trials Review, H2, 2017

8
Full Reports
Sleep Disorders Drug Development Pipeline Review,
2017
Contact us atBharat Book Bureau Tel 91 22
27810772 / 27810773 Email poonam_at_bharatbook.com O
ur Blog https//www.bharatbook.com/blog/ Twitter
https//twitter.com/researchbook Facebook
https//www.facebook.com/BharatBook3B LinkedIn
http//www.linkedin.com/company/bharat-book-bureau